Kiora Pharmaceuticals
Stefan acts as Executive Vice President CMC and Operations at Kiora. Previously, he was the co-founder and COO of Panoptes Pharma. Prior to this position he was global Project Manager at Nabriva Therapeutics AG, responsible for development of XENLETATM from early preclinical to clinical phase 2 programs. Before that he had various roles in R&D at Biovertis AG, Austria and Wilex AG, Germany.
He has profound knowledge of drug development and is an inventor on numerous patents. Dr. Stefan Sperl received his PhD in Medicinal Chemistry from the Max Planck Institute in Martinsried, Germany.
This person is not in any offices
Kiora Pharmaceuticals
Kiora Pharmaceuticals is a clinical-stage specialty pharmaceutical company that develops and commercializes products using two proprietary platform technologies for treating diseases and disorders of the eye.